All News

There are good reasons why we shouldn't permit lifestyle drugs on the market. But as a society, we've already shown that those reasons don't mean much to us.

Critics asked for a reevaluation of new drugs a year after launch. FDA's plan to issue report cards on new drugs responds to that demand-but not completely.

Partnerships with US drug firms haven't always worked out the way Japanese companies would have liked.

We all know that pharma is facing hard times: cut-throat competition, regulatory constraints, patent expirations, rusty pipelines, rising generics, falling revenues-and, perhaps most important, a firestorm of consumer anger over drug prices and safety now being restoked by the new Democratic Congress. Nevertheless, industry persists in "staying the course"-sound familiar?-rather than charting a bold new strategy. Its two top priorities remain opposing government price controls and thwarting patent laws favorable to generics. These defensive tactics are hardly the hallmark of leadership.

Companies like Amgen, J&J launch DTC efforts to raise awareness of biologics.

Merck ends controversial lobbying campaign for HPV vaccine, but was it the right move?

Unbranded effort with American Cancer Society will bolster patient education, compliance.

Drug giant is streamlining R&D to focus on five disease areas--three of them new.

First-ever Advance Market Commitment offers guaranteed price for vaccines in poor countries.

Patent challenge has hurt Sanofi-Aventis, Bristol-Myers Squibb, which are considering their next move.

CSL Biotherapies hires branding agency to prepare for possible product launch later this year.

Teva plans NBA-themed campaign for re-branded ProAir.

Companies put new emphasis on marketing to managed care.

Director Public Affairs, EMEA

FDA drug safety proposals don't represent major overhaul.

Drug giant cuts jobs, vows to speed up drug development.

Otsuka forms new strategic unit that will focus on development, commercialization.

PEE readership survey

PEE readership survey v. 2

February 2007 CE

PEE Readership Survey 2007

A new bill says HHS has to negotiate Medicare drug prices with pharma companies. It won't work-but that's not the biggest thing wrong with it.

Drug giant's new style features brains over brawn.

Physicians still slow to restrict prescribing data from sales reps as New Hampshire case goes to trial.

Unbranded campaign with American Heart Association kicks off with much fanfare.

PEE Reader Survey Jan 2007

FTC is looking to ban reverse-payment settlements and pharma must tread with caution.

Experts offer strategies for blocking repeal of non-interference bill.

Kindler's Strategic Direction Is Neither, Say Cranky Analysts